The Role of lncRNAs in Rare Tumors with a Focus on HOX Transcript Antisense RNA (HOTAIR)

Rare cancers are identified as those with an annual incidence of fewer than 6 per 100,000 persons and includes both epithelial and stromal tumors from different anatomical areas. The advancement of analytical methods has produced an accurate molecular characterization of most human cancers, suggesti...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2021-09, Vol.22 (18), p.10160
Main Authors: Liguori, Giuseppina, Cerrone, Margherita, De Chiara, Annarosaria, Tafuto, Salvatore, Tracey de Bellis, Maura, Botti, Gerardo, Di Bonito, Maurizio, Cantile, Monica
Format: Article
Language:English
Subjects:
Antisense RNA
Antisense therapy
Biomarkers
Bone cancer
Cell adhesion & migration
Cell cycle
Cell growth
Digestive system
Exocrine glands
Health care
HOTAIR
lncRNAs
Medical prognosis
Metastasis
MicroRNAs
Nervous system
Non-coding RNA
rare cancers
Review
Sarcoma
Transcription
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rare cancers are identified as those with an annual incidence of fewer than 6 per 100,000 persons and includes both epithelial and stromal tumors from different anatomical areas. The advancement of analytical methods has produced an accurate molecular characterization of most human cancers, suggesting a “molecular classification” that has allowed the establishment of increasingly personalized therapeutic strategies. However, the limited availability of rare cancer samples has resulted in very few therapeutic options for these tumors, often leading to poor prognosis. Long non coding RNAs (lncRNAs) are a class of non-coding RNAs mostly involved in tumor progression and drug response. In particular, the lncRNA HOX transcript antisense RNA (HOTAIR) represents an emergent diagnostic, prognostic and predictive biomarker in many human cancers. The aim of this review is to highlight the role of HOTAIR in rare cancers, proposing it as a new biomarker usable in the management of these tumors.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms221810160